Recent partnerships and acquisitions
- March 8, 2016 Ipsen announced a research partnership with Peptimimesis, a French start-up from a spin-off project of Strasbourg University and INSERM, the French national institute of health and medical research, to develop novel therapeutic peptides targeting a transmembrane receptor, which is overexpressed in a large number of cancers and is implicated in their development.
- March 1, 2016 Ipsen bolstered its oncology pipeline by acquiring the rights outside the US, Canada and Japan to Exelixis’ cabozantinib, a treatment today for medullary thyroid cancer and intended for advanced renal cell carcinoma with survival impact for patients.
- February 17, 2016: Ipsen strengthened its pipeline in niche indication by in-licensing novel radiopharmaceuticals from 3B Pharmaceuticals targeting a neurotensin receptor for the treatment of pancreatic adenocarcinoma.
- Acquisition of OctreoPharm Sciences in 2015, a company developing innovative radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumours.
- Option agreement in 2015 to acquire Canbex Therapeutics, a spin-out of University College London (UCL) upon completion of the phase IIa study of Canbex’s lead candidate VSN16R, indicated for spasticity in people with multiple sclerosis.
- Agreement with Actavis to distribute and promote Eziclen® / Izinova® (BLI-800) in the G5 countries (France, Germany, Italy, UK and Spain). In 2009, had acquired exclusive manufacturing, marketing and distribution rights of Braintree’s BLI-800 Eziclen® / Izinova® for countries including Europe, CIS and China.
- In 2015, Ipsen expanded its ties to Harvard University by signing a new Research Alliance Agreement.
- Commercialization agreement with Lexicon Pharmaceuticals Inc. in 2014 to market Telotristat etiprate outside North America and Japan with a focus on carcinoid syndrome. It was extended to Canada in March 2015.
- In 2014, Ipsen out-licensed patents, licenses know-how and data to Chinese Peptide Company for research in peptide programs.
- Licensing agreement with Otonomy Inc. in 2014 enabling Otonomy to utilize Ipsen’s gacyclidine data in the development of OTO-311 for the treatment of tinnitus.
- Promotion and distribution agreement with GW Pharma for their product Sativex® intended for the treatment of spasticity due to multiple sclerosis, in Latin America (excluding Mexico and the Caribbean).
- In 2013 Ipsen acquired Syntaxin in the UK, a leading toxin-research company. In the same year a research deal was signed with Harvard Medical School, both creating an expanded toxin environment for research and development for innovative toxins.
Early stage academic partners
- A*STAR P53LAB (Singapore)
- Brigham and Women’s Hospital, Boston (USA)
- Charité Medical School and Hospital, Berlin (Germany)
- G.B. Rossi Clinic, Verona (Italy)
- Hanover Medical School (Germany)
- Harvard Medical School (USA)
- Hôpital Saint-Antoine (France)
- Hôpital Pierre Wertheimer (France)
- INSERM (France)
- Institut du Cerveau et de la Moëlle Épinière (France)
- Institut Curie (France)
- Institut Gustave Roussy, Paris (France)
- Lund University, Malmö (Sweden)
- Massachusetts General Hospital, Boston (USA)
- Salk Institute, San Diego (USA)
- SNCC (Singapore)
- University of Cordoba (Spain)
- University of Genoa (Italy)
- University of Lund, Malmö (Sweden)
- University of Rome (Italy)
- University of Strasbourg (France)
- University Hospital, Uppsala (Sweden)